Meta-Flux develops an AI-driven platform that models disease biology to improve preclinical drug development. The platform integrates genetic, proteomic, and metabolic data to simulate biological systems and predict how potential drugs will behave, helping researchers identify viable targets, validate mechanisms of action, and make faster, evidence-based go/no-go decisions before entering costly clinical stages. Their goal is to increase accuracy in drug development, ensuring that successful drugs help the right people.